February 21, 2025

Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials

The recently approved menin inhibitor revumenib is poised to improve the treatment of acute leukemia, specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhib...

The ASCO Post

February 21, 2025

Early-Stage Classic Hodgkin Lymphoma

The recent history of classic Hodgkin lymphoma (cHL) clinical research and therapy has focused on therapy de-escalation while maintaining cure rates to reduce toxicity. Therapy adaptation with PET sca...

The ASCO Post

February 21, 2025

Jennifer A. Woyach, MD, Named The Ohio State’s Director of Hematology

Jennifer A. Woyach, MD, a hematology cancer expert and researcher who has been with The Ohio State for more than 12 years, has been named Director of the Division of Hematology at The Ohio State Unive...

The ASCO Post

February 21, 2025

How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer

Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a ve...

The ASCO Post

February 21, 2025

FDA Approves First Companion Diagnostic to Identify Patients With Metastatic Breast Cancer Eligible for T-DXd

The FDA has approved a label expansion for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be e...

The ASCO Post

February 21, 2025

Lung-MAP 3.0: Simplifying the Process to Meet Patients’ Needs

The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-...

The ASCO Post

February 21, 2025

New Blood-Based Screening Test Accurately Detects Colorectal Cancer Risk in Adults Aged 45 and Older

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths in the United States. This year, it’s expected that more than 53,000 individuals will die of the disease.1

The ASCO Post

February 21, 2025

Experimental Regimen Demonstrates Benefit in BRAF V600E–Mutant Metastatic Colorectal Cancer

The BRAF inhibitor encorafenib plus the monoclonal antibody cetuximab combined with mFOLFOX (modified folinic acid, fluorouracil, and oxaliplatin) significantly improved overall response in BRAF V600E...

The ASCO Post

February 21, 2025

ASCO Updates Guidelines on Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

ASCO has updated its guidelines on the role of neoadjuvant chemotherapy for patients newly diagnosed with advanced ovarian cancer, underscoring key considerations in selecting patients for treatment a...

The ASCO Post